Biomea Fusion, Inc.

Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.

BMEA | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 1599 INDUSTRIAL ROAD, 94070 SAN CARLOS
Website:: https://www.biomeafusion.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral covalent small molecules for the treatment of metabolic diseases and genetically defined cancers. The company's primary focus is on its metabolic franchise, advancing potential disease-modifying therapies for diabetes and obesity. Its lead clinical candidates include icovamenib (BMF-219), a covalent menin inhibitor being investigated for its potential to regenerate insulin-producing beta cells in patients with Type 1 and Type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist. The company's oncology pipeline features BMF-500, a covalent FLT3 inhibitor for acute leukemia. Biomea leverages its proprietary FUSION™ System to design its drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biomea Fusion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biomea Fusion, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Biomea Fusion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
BioAge Labs, Inc. Develops therapies for metabolic diseases like obesity by targeting the biology of human aging.	United States of America	BIOA
BioArctic Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.	Sweden	BIOA
BioAtla, Inc. Developing safer, conditionally active antibody therapies for solid tumor cancers.	United States of America	BCAB
BioCardia, Inc. Developing regenerative cell therapies for cardiovascular and pulmonary diseases.	United States of America	BCDA
Bioceltix S.A. Developing 'off-the-shelf' stem cell therapies for diseases in companion animals.	Poland	BCX
BIOCRYST PHARMACEUTICALS INC Develops oral small-molecule drugs for rare diseases like hereditary angioedema.	United States of America	BCRX
Biodexa Pharmaceuticals Plc Develops treatments for rare diseases, diabetes, and cancer using proprietary drug delivery tech.	United States of America	BDRX
Biofarm S.A. A top domestic manufacturer of pharmaceuticals, supplements, and soft gelatin capsules.	Romania	BIO
Biofrontera AG Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.	Germany	B8F
Biofrontera Inc. Biopharma firm commercializing photodynamic therapy & antibiotics for skin conditions.	United States of America	BFRI